Last deal
Amount
Stage
Date
all rounds
Total amount
date founded
Financing round
General
About Company
Industry
Sector :
Subsector :
founded date
founders
Number of employees
Company Type
Last funding type
IPO status
Contacts
Similar Companies1000
Actym Therapeutics, Inc.
Actym Therapeutics is a privately-held biotech company focused on developing novel immuno-oncology therapies to treat cancer.
Sector
Subsector
Location
total rounds
total raised
Genagon Therapeutics
Genagon Therapeutics is a biopharmaceutical company that develops a unique method for treating cancer.
Sector
Subsector
Keywords
Location
total rounds
total raised
BliNK Biomedical
BliNK Biomedical specializes in developing antibody-based therapeutics for life-threatening diseases such as cancer.
Sector
Subsector
Keywords
Location
total rounds
total raised
Tusk Therapeutics
Tusk Tx develops therapeutic antibodies to treat cancer by harnessing the immune system.
Sector
Subsector
Keywords
Location
total rounds
total raised
Financials
Funding Rounds2
Number of Funding Rounds
Money Raised
Their latest funding was raised on 16.06.2020. Their latest investor Asabys Partners. Their latest round Series A
Asabys Partners
Asabys Partners is a venture capital firm that invests in human healthcare.
Sector
Subsector
Location
total rounds
total raised
count Of Investments
count Of Exists
Co-Investors
Investors5
Number of lead investors
Number of investors
Asabys Partners
Asabys Partners is a venture capital firm that invests in human healthcare.
Sector
Subsector
Location
total rounds
total raised
count Of Investments
count Of Exists
Bpifrance
Bpifrance is a French public investment bank.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Jean-François Morin
Jean-François Morin is a Principal of Bpifrance.
Ysios Capital
Ysios Capital provides venture capital funding to Spanish life science companies.
Sector
Subsector
Keywords
Location
count Of Investments
count Of Exists
Joel Jean Mairet
Joël oversees all operations at Ysios Capital, including management, strategy and standard operations. Joël serves on the board of TiGenix, AM-Pharma, MedLumics, and is chairman of the board at Inbiomotion. Formerly, he was board observer at Biovex (now AMGEN) and chairman of the board at Cellerix (now TiGenix). Previously, Joël co-founded GLYCART Biotechnology AG (Zürich, Switzerland) in March 2001 and was Chief Executive since inception. He raised €15 million in three rounds of financing for GLYCART before the company was sold to F.Hoffmann-La Roche Ltd in July 2005, a deal lauded as the deal of the year by the European Venture Capital magazine. As Chief Executive, he led all the fund-raising efforts, established a pan-European investment syndicate with leading venture capital firms and structured, negotiated and executed several key in- and out-licensing agreements with global pharmaceutical and biotechnology companies. Joël holds a master’s degree in Biochemistry, with a specialization in Biotechnology, and a PhD in the fields of cell biology and immunotherapeutics, both from the Swiss Federal Institute of Technology (ETH) in Zürich. He was elected one of the 50 key players in biotechnology in Switzerland in 2003 and earned several innovation awards for GLYCART, including the Wall Street Journal Europe Innovation Award in 2001.
current job
People
Founders2
Salvador Aznar Benitah
current job
organization founded
Salvador Aznar Benitah
Employee Profiles2
Salvador Aznar Benitah
Founder and Scientific Advisor